Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:MDXH

MDxHealth Q1 2026 Earnings Report

MDxHealth logo
$2.02 +0.02 (+1.00%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$2.04 +0.02 (+0.99%)
As of 05/6/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

MDxHealth EPS Results

Actual EPS
N/A
Consensus EPS
-$0.14
Beat/Miss
N/A
One Year Ago EPS
N/A

MDxHealth Revenue Results

Actual Revenue
N/A
Expected Revenue
$30.89 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MDxHealth Announcement Details

Quarter
Q1 2026
Date
5/13/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 13, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

MDxHealth Earnings Headlines

Mdxhealth to Release First Quarter 2026 Financial Results on May 13
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3285403/0/en/mdxhealth-to-release-first-quarter-2026-financial-results-on-may-13.html
Mdxhealth Earnings Call Highlights Fast Growth, Rising Costs
March 31, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDXH/pressreleases/627176/mdxhealth-earnings-call-highlights-fast-growth-rising-costs/
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.tc pixel
 |  American Alternative (Ad)
Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)
March 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PTGX/pressreleases/913452/analysts-are-bullish-on-top-healthcare-stocks-protagonist-therapeutics-ptgx-mdxhealth-mdxh/
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
March 16, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/mdxhealth-highlights-data-from-oxford-s-prompt-study-demonstrating-the-genomic-prostate-score-gps-test-predicts-adverse-outcomes-across-multiple-treatment-settings-at-eau-2026-1035934707
Mdxhealth Highlights Data from Oxford's ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
March 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/16/3256649/0/en/mdxhealth-highlights-data-from-oxford-s-prompt-study-demonstrating-the-genomic-prostate-score-gps-test-predicts-adverse-outcomes-across-multiple-treatment-settings-at-eau-2026.html
See More MDxHealth Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MDxHealth? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MDxHealth and other key companies, straight to your email.

About MDxHealth

MDxHealth (NASDAQ:MDXH), headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx. ConfirmMDx is an epigenetic assay performed on prostate biopsy tissue to identify men at risk of harboring occult high-grade prostate cancer following a negative biopsy result. SelectMDx is a non-invasive urine test designed to assess the likelihood of clinically significant prostate cancer before an initial biopsy, helping to reduce unnecessary procedures. Both tests are performed in MDxHealth’s CLIA-certified laboratory in the United States and its ISO-certified laboratory in Europe, and are used by urologists worldwide to guide biopsy and treatment decisions.

Founded in 2003, MDxHealth has established a global footprint, serving patients and healthcare providers across North America, Europe and select international markets through direct lab services and strategic partnerships. The company is led by President and CEO Caroline Palm, who brings extensive experience in molecular diagnostics and life sciences. MDxHealth is publicly traded on the Nasdaq under the ticker symbol MDXH.

View MDxHealth Profile
Earnings Tools